Results 131 to 140 of about 2,460 (174)

Spermicides, HIV, and the Vaginal Sponge

JAMA: The Journal of the American Medical Association, 1992
Despite the current epidemic of sexually transmitted human immunodeficiency virus (HIV) infection and other sexually transmitted diseases (STDs), prevention measures known to be effective are underutilized. Most prevention guidelines have appropriately emphasized abstinence, monogamy between uninfected partners, or condom use.
K M, Stone, H B, Peterson
openaire   +3 more sources

Implementation of a Protocol to Reduce Occurrence of Retained Sponges After Vaginal Delivery [PDF]

Military Medicine, 2011
Retained sponges (gossypiboma) following vaginal delivery are an uncommon occurrence. Although significant morbidity from such an event is unlikely, there are many reported adverse effects, including symptoms of malodorous discharge, loss of confidence in providers and the medical system, and legal claims.To report a protocol intended to reduce the ...
Everett Magann, Mónica Lutgendorf, Magann Everett F   +2 more
exaly   +3 more sources

Food and Drug Administration Approves Vaginal Sponge

Family Planning Perspectives, 1983
On April 1 1983 the US Food and Drug Administration (FDA) approved a disposable vaginal sponge of soft polyurethane foam saturated with 1 gm of nonoxynol-9 as a nonprescription contraceptive offering 2 improvements over products already available: ability to leave in place up to 24 hours and no need for additional application of spermicide for ...
D, Kafka, R B, Gold
openaire   +2 more sources

Mucoadhesive cellulosic derivative sponges as drug delivery system for vaginal application

European Journal of Pharmaceutics and Biopharmaceutics, 2015
Vaginal delivery of active drugs has been largely studied for local and systemic applications. It is well known that vagina is a complex route, due to physiological and non-physiological changes. Therefore, in order to achieve a prolonged local effect, these variations have to be considered.
Anna Lechanteur, Tania Fürst, Brigitte Evrard   +2 more
exaly   +4 more sources

Metronidazole-containing vaginal sponges for the treatment of bacterial vaginosis

Advances in Contraception, 1986
Currently, there is no FDA approved treatment for bacterial vaginosis (BV), although various oral dosages of metronidazole are used to treat this condition. A vaginal therapeutic sponge (VLI Corporation) that releases metronidazole over a 24 h use period has been developed for the treatment of BV. Each sponge contains 250 mg of metronidazole.
W E, Brenner, J R, Dingfelder
openaire   +2 more sources

Vaginal bacteria flora concurred with vaginal sponges in black Iraqi goats [PDF]

Iraqi Journal of Veterinary Sciences, 2012
The aim of this study was to identify the vaginal bacteria flora in black Iraqi goats subjected to estrus synchronization. Sixteen multiparous black Iraqi goats presented in the farm of the College Veterinary Medicine, Al-Anbar University, were included in this study, during the breeding season, from May 2011 to July 2011. The ages of the animals rwere
A.F. Majeed, H.M. Al-Rawi, S.M.A. Al-Kubaisi, T.M.N. Al-Jumaily   +3 more
exaly   +2 more sources

A System-Wide Initiative to Prevent Retained Vaginal Sponges

MCN: The American Journal of Maternal/Child Nursing, 2011
As any perinatal nurse knows, retained vaginal sponges are an obstetrical and postpartum patient safety problem. As surgical sponge counts are not routine in some obstetrical units for vaginal births, our healthcare system chose to institute a rigorous process to eliminate retained sponges in all vaginal births.
Brenda A, Chagolla, Verna C, Gibbs, John P, Keats, Barbara, Pelletreau   +3 more
openaire   +2 more sources

Worldwide method effectiveness of the Today® vaginal contraceptive sponge

Advances in Contraception, 1985
The Today vaginal contraceptive sponge is made of polyurethane and contains 1 gram of the spermicide nonoxynol-9. Following preclinical and phase I and II clinical trials, extensive worldwide phase III trials were conducted. These multiclinic trials were conducted according to a common protocol with regularly scheduled follow-up visits and examinations.
D A, McClure, D A, Edelman
openaire   +2 more sources

Comparison of Medroxyprogesterone Acetate Orally and in Vaginal Sponges for Synchronizing Estrus in Ewes

Journal of Animal Science, 1970
H A Glimp, Dutt R H, R H Dutt
exaly   +3 more sources

The Vaginal Contraceptive Sponge

The Nurse Practitioner, 1984
The Today vaginal contraceptive sponge is a non-prescription barrier contraceptive which, after rigorous testing, was recently approved by the Food and Drug Administration (FDA) and marketed nationally. It is a cup-shaped white polyurethane sponge six cm in diameter and 1.5 cm thick, with a removal loop.
openaire   +2 more sources